Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry.

2 Dividend Stocks to Buy Hand Over Fist in November was originally published by The Motley Fool Their recent issues are ...

Snap’s flagship product is the smartphone app Snapchat, which allows its users to communicate via ephemeral short videos and ...

Thanks to a new unified hardware architecture based on Arm CPU cores, R-Car Gen 5 developers can reuse the same software and tools and applications from Renesas' broad line of new 64-bit SoCs and ...

Arcutis Biotherapeutics has returned an impressive +200% YTD, following the successful product launch of Zoryve. See why I rate ARQT stock as a Strong Buy.

AZN beats third-quarter estimates for earnings and sales. It raises its sales and profit outlook for 2024 for the second time ...

Oil and gas major Shell on Tuesday won an appeal against a landmark ruling that required it to accelerate carbon reduction ...

Amidst a (r)evolution in pharmaceutical strategy, Real World Evidence is more than ever a key driver of growing innovation in product life ... the full expert speaker line-up and content-packed ...

Several key players are shaping the global pruritus therapeutics market. Companies such as Allergan Inc., Amgen Inc., Astellas Pharma Inc., CARA Therapeutics, Novartis AG, and Teva Pharmaceutical ...

Analysts have suggested that Lumykras could become a $1 billion-plus product if Amgen can extend the label for the drug into the first-line NSCLC setting and get approval for other KRAS-mutated ...

Citi has started coverage of Gilead Sciences (NASDAQ:GILD) and Vertex Pharmaceuticals (NASDAQ:VRTX) at buy saying the former will benefit from short-term growth of Biktarvy (bictegravir, emtricitabine ...

Sales of tislelizumab totaled $163 million in the third quarter of 2024, representing growth of 13% compared to the ...